A
1.98
-0.08 (-3.88%)
| Previous Close | 2.06 |
| Open | 2.05 |
| Volume | 541,781 |
| Avg. Volume (3M) | 461,771 |
| Market Cap | 143,188,224 |
| Price / Book | 2.91 |
| 52 Weeks Range | |
| Earnings Date | 26 Oct 2026 |
| Diluted EPS (TTM) | -1.94 |
| Total Debt/Equity (MRQ) | 19.15% |
| Current Ratio (MRQ) | 8.02 |
| Operating Cash Flow (TTM) | -102.48 M |
| Levered Free Cash Flow (TTM) | -63.62 M |
| Return on Assets (TTM) | -31.31% |
| Return on Equity (TTM) | -55.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Acumen Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
-0.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.67 |
Select this tab to load the latest available analysis.
|
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.46% |
| % Held by Institutions | 72.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Knollwood Investment Advisory, Llc | 30 Jun 2026 | 1,628,510 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |